The COVID-19 Cytokine Storm; What We Know So Far

Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah, Rasha Khattab, Ramy Salem, Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah, Rasha Khattab, Ramy Salem

Abstract

COVID-19 is a rapidly spreading global threat that has been declared as a pandemic by the WHO. COVID-19 is transmitted via droplets or direct contact and infects the respiratory tract resulting in pneumonia in most of the cases and acute respiratory distress syndrome (ARDS) in about 15 % of the cases. Mortality in COVID-19 patients has been linked to the presence of the so-called "cytokine storm" induced by the virus. Excessive production of proinflammatory cytokines leads to ARDS aggravation and widespread tissue damage resulting in multi-organ failure and death. Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality.

Keywords: ARDS; COVID-19; IL-6; cytokine; storm.

Copyright © 2020 Ragab, Salah Eldin, Taeimah, Khattab and Salem.

References

    1. WHO Novel Coronavirus (2019-nCoV) Situation Report 1. (2020). Available online at: (accessed April 01, 2020).
    1. WHO Novel Coronavirus (2019-nCoV) Situation Report 22. (2020). Available online at: (accessed April 01, 2020).
    1. WHO Coronavirus disease 2019 (COVID-19) Situation Report 52. (2020). Available online at: (accessed April 01, 2020).
    1. WHO . Coronavirus disease 2019 (COVID-19) Situation Report 127. (2020). Available online at: (accessed May 27, 2020).
    1. Peng Z, Xing-Lou Y, Xian-Guang W, Ben H, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7
    1. Guo Y, Cao Q, Hong Z, Tan Y, Chen S-D, Jin H-J, et al. . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res. (2020) 7:11. 10.1186/s40779-020-00240-0
    1. Zhao S, Zhuang Z, Ran J, Lin J, Yang G, Yang L, et al. . The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: a data-driven correlational report. Travel Med Infect Dis. (2020) 33:101568. 10.1016/j.tmaid.2020.101568
    1. Wang X, Pan Z, Cheng Z. Association between 2019-nCoV transmission and N95 respirator use. J Hosp Infect. (2020) 105:104–5. 10.1101/2020.02.18.20021881
    1. Chan J, Yuan S, Kok K, To K, Chu H, Yang J, et al. . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. 10.1016/S0140-67362030154-9
    1. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. . Presumed asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–7. 10.1001/jama.2020.2565
    1. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. (2020) 158: 1518–9. 10.1053/j.gastro.2020.02.054
    1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2,143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. (2020) 145:e20200702 10.1542/peds.2020-0702
    1. Le H, Nguyen L, Tran D, Do H, Tran HT, Le YT, et al. The first infant case of COVID-19 acquired from a secondary transmission in Vietnam. Lancet Child Adolesc Health. (2020) 4:405–6. 10.1016/S2352-46422030091-2
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/S0140-67362030566-3
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. 10.1016/S0140-67362030211-7
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-67362030183-5
    1. Lai C, Shih T, Ko W, Tang H, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. (2020) 55:105924. 10.1016/j.ijantimicag.2020.105924
    1. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. (2020) 87:281–6. 10.1007/s12098-020-03263-6
    1. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for maortality in hospitalized patients with COVID-19. J Infect. (2020) 323:1406–7. 10.1016/j.jinf.2020.04.002
    1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. (2020) 46:846–8. 10.1007/s00134-020-06028-z
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. . Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. (2020) 130:2620–9. 10.1101/2020.02.16.20023903
    1. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. . Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. (2020) 92:791–6. 10.1002/jmv.25770
    1. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. (2020) 43:203–8. 10.3760/cma.j.issn.1001-0939.2020.0005
    1. Sun D, Li H, Lu X, Xiao H, Ren J, Zhang F-R, et al. . Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. (2020) 19:1–9. 10.1007/s12519-020-00354-4
    1. Braciale T, Hahn Y. Immunity to viruses. Immunol Rev. (2013) 255:10.1111/imr.12109. 10.1111/imr.12109
    1. Thompson M, Kaminski J, Kurt-Jones E, Fitzgerald K. Pattern recognition receptors and the innate immune response to viral infection. Viruses. (2011) 3:920–40. 10.3390/v3060920
    1. Shimizu M. Clinical features of cytokine storm syndrome. In: Cron R, Behrens E. editors. Cytokine Storm Syndrome. Cham: Springer; (2019). 31–42. 10.1007/978-3-030-22094-5_3
    1. Ishikawa T. Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus. J Pharmacogenom Pharmacoproteomics. (2012) 3:e131 10.4172/2153-0645.1000e131
    1. Kalaiyarasu S, Kumar M, Senthil Kumar D, Bhatia S, Dash SK, Bhat S, et al. Highly pathogenic avian in?uenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte-derived dendritic cells. Microbiol Immunol. (2016) 60:687–93. 10.1111/1348-0421.12443
    1. Woo P, Tung E, Chan K, Lau C, Lau SKP, Yuen K-Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis. (2010) 201:346–53. 10.1086/649785
    1. Lau S, Lau C, Chan K, Li C, Chen H, Jin D-Y, et al. . Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. (2013) 94:2679–90. 10.1099/vir.0.055533-0
    1. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. (2017) 39:529–39. 10.1007/s00281-017-0629-x
    1. Behrens E, Kreiger P, Cherian S, Cron R. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. (2006) 33:2081–4.
    1. Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, et al. . Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. (2019) 13:610–7. 10.1007/s11684-019-0714-8
    1. Xu X, Han M, Li T, Sun W, Wang D, et al. . Effective treatment of severe COVID-19 patients with Tocilizumab. Proc Natl Acad Sci USA. 117:11970–5. 10.1073/pnas.2005615117
    1. Available online at:

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner